Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 213.95
(-1.86%)
INR 213.95
(-1.86%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 755.45 Million | 2.3 Billion | 1.37 Billion | 2.52 Billion | 768.14 Million | 1.82 Billion |
| Cost of Revenue | 364.38 Million | 1.71 Billion | 1.26 Billion | 2.06 Billion | 1.93 Billion | 1.6 Billion |
| Gross Profit | 391.06 Million | 592 Million | 105.51 Million | 465.55 Million | -1.16 Billion | 224.41 Million |
| Operating Expenses | 3.07 Billion | 2.93 Billion | 2.06 Billion | 1.92 Billion | 1.98 Billion | 1.74 Billion |
| Selling, General and Administrative Expenses | -1.91 Billion | 1.31 Billion | 695.22 Million | 519.34 Million | 439.2 Million | 560.33 Million |
| Research and Development Expenses | 4.79 Billion | 4.52 Billion | 3.23 Billion | 3.87 Billion | 3.86 Billion | 1.47 Billion |
| Other Expenses | -2.14 Billion | 108.8 Million | 771 Thousand | 4.71 Million | 310 Thousand | 9.3 Million |
| Cost and Expenses | 4.87 Billion | 4.64 Billion | 3.33 Billion | 3.98 Billion | 3.91 Billion | 3.34 Billion |
| Operating Income | -4.11 Billion | -2.14 Billion | -1.96 Billion | -1.45 Billion | -3.14 Billion | -1.52 Billion |
| Interest Expense | 16.9 Million | 76.3 Million | 133.28 Million | 106.5 Million | 26.74 Million | 939 Thousand |
| Income Tax Expense | 3.82 Million | 117.47 Million | 14.81 Million | 43.82 Million | -15.73 Million | -5.6 Million |
| Earnings before Tax | -3.86 Billion | -2.22 Billion | -2.03 Billion | -1.51 Billion | -3.12 Billion | -1.45 Billion |
| Net Income | -3.87 Billion | -2.22 Billion | -2.03 Billion | -1.51 Billion | -3.12 Billion | -1.45 Billion |
| Earnings Per Share Basic | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | -5.69 |
| Earnings Per Share Diluted | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | -5.69 |
| Weighted Average Shares Outstanding | 324.56 Million | 284.69 Million | 263.14 Million | 262.04 Million | 262.04 Million | 255.59 Million |
| Weighted Average Shares Outstanding (Diluted) | 324.52 Million | 284.69 Million | 263.14 Million | 262.04 Million | 262.04 Million | 255.59 Million |
| Gross Margin | 0.52 | 0.26 | 0.08 | 0.18 | -1.52 | 0.12 |
| EBIT Margin | -4.94 | -0.88 | -1.35 | -0.52 | -4.00 | -0.79 |
| Profit Margin | -5.13 | -0.96 | -1.48 | -0.60 | -4.07 | -0.80 |
| EBITDA | -3.73 Billion | -2.03 Billion | -1.79 Billion | -1.29 Billion | -3 Billion | -1.37 Billion |
| Earnings Before Tax Margin | -5.45 | -0.93 | -1.43 | -0.58 | -4.10 | -0.83 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 128.6 Million | 168.1 Million | 755.5 Million | 165.6 Million | 138.6 Million | 211.8 Million |
| Cost of Revenue | 499.5 Million | 619.3 Million | 1.82 Billion | 605.6 Million | 327.4 Million | 246.8 Million |
| Gross Profit | -370.9 Million | -451.2 Million | -1.06 Billion | -440 Million | -188.8 Million | -35 Million |
| Operating Expenses | 689.8 Million | 513.79 Million | 3.07 Billion | 649 Million | 869 Million | 911.5 Million |
| Selling, General and Administrative Expenses | 434.5 Million | 328.4 Million | - | 424.5 Million | 398.2 Million | 418.8 Million |
| Research and Development Expenses | 255.3 Million | 185.4 Million | - | 224.5 Million | 237.1 Million | 182.1 Million |
| Other Expenses | - | 15.6 Million | 294.7 Million | 44 Million | 63.9 Million | 84.9 Million |
| Cost and Expenses | 1.18 Billion | 1.13 Billion | 4.9 Billion | 1.25 Billion | 1.19 Billion | 1.15 Billion |
| Operating Income | -1.06 Billion | -965 Million | -4.14 Billion | -1.08 Billion | -993.9 Million | -861.6 Million |
| Interest Expense | 11.4 Million | 5.6 Million | 16.9 Million | 9.1 Million | 2.6 Million | 2.6 Million |
| Income Tax Expense | 1.6 Million | 4 Million | 3.8 Million | 3.8 Million | 31.63 Million | 31.67 Million |
| Earnings before Tax | -1.07 Billion | -955 Million | -3.86 Billion | -1.05 Billion | -996.5 Million | -864.2 Million |
| Net Income | -1.07 Billion | -959 Million | -3.87 Billion | -1.05 Billion | -996.5 Million | -864.2 Million |
| Earnings Per Share Basic | -3.31 | -2.96 | - | -3.26 | -3.07 | -2.66 |
| Earnings Per Share Diluted | -3.31 | -2.96 | - | -3.26 | -3.07 | -2.66 |
| Weighted Average Shares Outstanding | 324.52 Million | 324.52 Million | 324.56 Million | 324.52 Million | 324.52 Million | 324.52 Million |
| Weighted Average Shares Outstanding (Diluted) | 324.52 Million | 324.52 Million | 324.56 Million | 324.52 Million | 324.52 Million | 324.52 Million |
| Gross Margin | -2.88 | -2.68 | -1.42 | -2.66 | -1.36 | -0.17 |
| EBIT Margin | -8.00 | -5.55 | - | -6.39 | -6.94 | -3.92 |
| Profit Margin | -8.35 | -5.70 | -5.13 | -6.39 | -7.19 | -4.08 |
| EBITDA | -1.02 Billion | -933.6 Million | - | -1.05 Billion | -962.3 Million | -829.8 Million |
| Earnings Before Tax Margin | -8.25 | -5.74 | -5.49 | -6.58 | -7.17 | -4.07 |
CLGOF
OTM
AVIV
600448
VIVR3
CRAB